CD274 and neoplasm: In the Keynote-522 trial, tumor samples were considered PD-L1-positive based on a CPS ≥ 1; however, a better pathological complete response in patients treated with pembrolizumab was observed regardless of the PD-L1 immunohistochemical expression [41].